<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Organizing :: Changing :: Communicating &#187; drugs</title>
	<atom:link href="http://www.turris-consulting.de/wordpress/tag/drugs/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.turris-consulting.de/wordpress</link>
	<description>Organizational Change and Business Communication</description>
	<lastBuildDate>Sun, 21 Mar 2010 20:00:00 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Pharma companies and Corporate Social Responsibility</title>
		<link>http://www.turris-consulting.de/wordpress/pharma-companies-corporate-social-responsibility/</link>
		<comments>http://www.turris-consulting.de/wordpress/pharma-companies-corporate-social-responsibility/#comments</comments>
		<pubDate>Wed, 20 Jan 2010 10:55:44 +0000</pubDate>
		<dc:creator>itowers</dc:creator>
				<category><![CDATA[Corporate Social Responsibility]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[developing countries]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>

		<guid isPermaLink="false">http://www.turris-consulting.de/wordpress/?p=579</guid>
		<description><![CDATA[One of the main challenges for pharma companies is how to balance the needs of the various stakeholders involved. Employees, shareholders and patients all have different needs. A particularly tricky problem is pricing: what we in the rich countries can afford is very often too expensive for poorer countries.
I was interested to read what Andrew [...]]]></description>
			<content:encoded><![CDATA[<p>One<img class="alignleft size-medium wp-image-581" style="margin: 2px;" title="gsk" src="http://www.turris-consulting.de/wordpress/wp-content/uploads/2010/01/gsk-300x264.jpg" alt="gsk" width="126" height="111" /> of the main challenges for pharma companies is how to balance the needs of the various stakeholders involved. Employees, shareholders and patients all have different needs. A particularly tricky problem is pricing: what we in the rich countries can afford is very often too expensive for poorer countries.</p>
<p>I was interested to read what Andrew Witty, the boss of GlaxoSmithKline, says in the Guardian -<a href=" http://www.guardian.co.uk/science/2010/jan/20/glaxo-malaria-drugs-public-domain" target="_blank"> Glaxo offers free access to potential malaria cures</a>. His company is is putting 13,500 compounds that might cure malaria into the public domain.</p>
<p>According to the article,</p>
<blockquote><p>Andrew Witty, the British boss of Glaxo-SmithKline, will say in a major speech that multinational drug companies have to balance social responsibility alongside the need to make profits for their shareholders. There is, he will say, an &#8220;imperative to earn the trust of society, not just by meeting expectations but by exceeding them&#8221;.</p></blockquote>
<p>This is a very welcome move. Now, it&#8217;s to be hoped that other pharma companies will follow suit. It&#8217;s also to be hoped that GSK and the other companies do even more to benefit people in poorer countries who are suffering from other illnesses.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.turris-consulting.de/wordpress/pharma-companies-corporate-social-responsibility/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
	</channel>
</rss>

